These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 22708276)

  • 1. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
    Charliński G; Wiater E; Jedrzejczak WW
    Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
    Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
    Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
    Adam Z; Pour L; Krejcí M; Zahradová L; Krivanová A; Mardová J; Kovárová L; Stepánková S; Moulis M; Kren L; Veselý K; Svobodová I; Germáková Z; Nedbálková M; Mayer J; Hájek R
    Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Light-chain amyloidosis: SCT, novel agents and beyond.
    Rosenzweig M; Giralt S; Landau H
    Bone Marrow Transplant; 2013 Aug; 48(8):1022-7. PubMed ID: 23103675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.
    Kristinsson SY; Landgren O; Rajkumar VS
    Cancer J; 2009; 15(6):473-8. PubMed ID: 20010166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
    Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Light chain amyloidosis--clinical symptoms, update diagnosis, and treatment].
    Charliński G; Jurczyszyn A; Wiktor-Jedrzejczak W
    Przegl Lek; 2014; 71(2):102-9. PubMed ID: 25016786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2016 Sep; 91(9):947-56. PubMed ID: 27527836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
    Suzuki K
    Clin Exp Nephrol; 2012 Oct; 16(5):659-71. PubMed ID: 22968855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [AL amyloidosis].
    Gadó K; Domján G
    Orv Hetil; 2012 Apr; 153(15):563-73. PubMed ID: 22472357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
    Sher T; Hayman SR; Gertz MA
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
    Dinner S; Witteles W; Afghahi A; Witteles R; Arai S; Lafayette R; Schrier SL; Liedtke M
    Haematologica; 2013 Oct; 98(10):1593-9. PubMed ID: 23716538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
    Pika T; Lochman P; Vymětal J; Metelka R; Minařík J; Látalová P; Zapletalová J; Bačovský J; Ščudla V
    Klin Onkol; 2013; 26(5):343-7. PubMed ID: 24107157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Part II: role of maintenance therapy in transplant-ineligible patients.
    Palumbo A; Mina R
    J Natl Compr Canc Netw; 2013 Jan; 11(1):43-9. PubMed ID: 23307980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
    Palladini G; Russo P; Milani P; Foli A; Lavatelli F; Nuvolone M; Perlini S; Merlini G
    Haematologica; 2013 Mar; 98(3):433-6. PubMed ID: 22983583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.